tirzepatide on shortage list Lilly's weight-loss drug removed from FDA's END OF TIRZEPATIDE COMPOUNDING? FDA

Weight loss stalls Plateaus happen

ISO 9001:2015 facility used

doi: 10.1016/j.atherosclerosis.2015.05.005 144 TuttolomondoA.Di RaimondoD.PecoraroR.ArnaoV.PintoA.LicataG

Current clinical consensus reflects the following: Research findings are preliminary and insufficient to guide treatment decisions No regulatory approval exists for using GLP-1s in addiction treatment Early signals do not outweigh the lack of long-term outcome data Instead, clinicians continue to recommend established, evidence-based approaches, including: Behavioral therapies tailored to substance use disorders Medication-assisted treatment when medically indicated Comprehensive psychosocial support and relapse-prevention planning Comprehensive assessment remains a cornerstone of safe and effective care

Each of these experiments was independently repeated 3 times